TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6785791

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31833452

Group type: EXPERIMENTAL
Intervention: Web-based information tool and nurse delivered telephone support
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study: 30655568

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily for 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study: 28407735

Group type: EXPERIMENTAL
Intervention: Telbivudine treatment starting at 12 weeks (Group A; n=62)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Telbivudine treatment starting at 20-28 weeks (Group B; n=61)
Number of subjects: 188

Group type: COMPARATOR
Intervention: No antiviral treatment (Group C; n=65)
Number of subjects: 188
Study: 27697880

Group type: COMPARATOR
Intervention: Education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education + Feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 0
Study: 24369433

Group type: EXPERIMENTAL
Intervention: Stigma reduction intervention in healthcare settings
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 217
Study: 22499579

Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Probabilistic approach to mismatch definition
Number of subjects: 62
Study: 19852303

Group type: EXPERIMENTAL
Intervention: Guilong Tongluo Capsule (GTC) combined with prednisone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 60
Study: 17052823

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Care interventions including acupuncture
Number of subjects: 205

Group type: COMPARATOR
Intervention: Non-acupuncture group
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Presence of Group B streptococci in breast milk
Number of subjects: 205
Study: 15102339

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 1200 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Celecoxib (Celebrex) 200 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both SAMe and celecoxib
Number of subjects: 61
Study: 12054376

Group type: EXPERIMENTAL
Intervention: Gray lens tint
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Brown lens tint
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Yellow lens tint
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Green lens tint
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Purple lens tint
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Blue lens tint
Number of subjects: 25

Group type: COMPARATOR
Intervention: Clear lens
Number of subjects: 25
Study: 9665109

Group type: EXPERIMENTAL
Intervention: whole-protein-based formula (n = 22)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: peptide-based formula (n = 17)
Number of subjects: 49

Group type: COMPARATOR
Intervention: nonsupplemented, nonrandomly assigned group (n = 13)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: whole-protein-based and peptide-based formulas
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: baseline synthesis of fat (de novo hepatic lipogenesis)
Number of subjects: 49
Study: 7666247

Group type: EXPERIMENTAL
Intervention: 3.4 mumol isoflavones/kg body wt in soymilk
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 6.9 mumol isoflavones/kg body wt in soymilk
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 10.3 mumol isoflavones/kg body wt in soymilk
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: In vitro anaerobic incubation of isoflavones with human feces
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Subjects excreting large amounts of fecal isoflavones
Number of subjects: 7
Study: 2693995

Group type: EXPERIMENTAL
Intervention: l-tryptophan
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 34
Study: 361988

Group type: EXPERIMENTAL
Intervention: Prazosin hydrochloride
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prazosin with polythiazide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clonidine with chlorthalidone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prazosin and clonidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prazosin and diuretics
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clonidine and diuretics
Number of subjects: 30
Study: 30644982

Group type: EXPERIMENTAL
Intervention: Pooled donor FMT (n=38)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Autologous FMT (n=35)
Number of subjects: 73
Study: 28608013

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (6 mmHg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (12 mmHg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 64
Study: 24647318

Group type: EXPERIMENTAL
Intervention: Modified nonclipped harvesting technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional clipped harvesting technique
Number of subjects: 40
Study: 23641803

Group type: EXPERIMENTAL
Intervention: Multi-modal intervention including a computerized patient activation tool, a web-based COPD guideline tool, and a COPD patient education toolkit.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient activation tool 'MyLungAge'.
Number of subjects: 30
Study: 21377168

Group type: EXPERIMENTAL
Intervention: Social Cognitive Skills Training (SCST)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Computerized neurocognitive remediation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard illness management skills training
Number of subjects: 68

Group type: COMPARATOR
Intervention: Hybrid treatment (SCST and neurocognitive remediation)
Number of subjects: 68
Study: 19646443

Group type: EXPERIMENTAL
Intervention: Lanreotide (120 mg) administered every 28 days for 24 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 17874925

Group type: EXPERIMENTAL
Intervention: Family-centered intervention to reduce disruptive behavior
Number of subjects: 120
Study: 15359673

Group type: EXPERIMENTAL
Intervention: Bent-handle pliers
Number of subjects: 16

Group type: COMPARATOR
Intervention: Straight-handle pliers
Number of subjects: 16
Study: 11318525

Group type: EXPERIMENTAL
Intervention: 3 MU of IFN‐beta twice daily for four weeks (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 6 MU once a day for four weeks (group B)
Number of subjects: 60
Study: 9007770

Group type: EXPERIMENTAL
Intervention: Short CPM duration (3-5 hours per day) with CPM ROM increased 5 degrees twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Short CPM duration with CPM ROM increased daily to patient tolerance
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Long CPM duration (10-12 hours per day) with CPM ROM increased 5 degrees twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Long CPM duration with CPM ROM increased daily to patient tolerance
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined CPM groups (short and long durations)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patient-preferred CPM duration
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patient-preferred CPM incremental increase in ROM
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 8110435

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.5 g/day) for 8 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 2944688

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) during water immersion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control experiments (no water immersion)
Number of subjects: 0
Study: 29490466

Group type: EXPERIMENTAL
Intervention: Function and Behavior Focused Care intervention
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control group (nonfallers)
Number of subjects: 336
Study: 27678295

Group type: EXPERIMENTAL
Intervention: Vigil (1.0×10^7 cells/intradermal injection/month for 4 to 12 doses)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 42
Study: 24101716

Group type: EXPERIMENTAL
Intervention: Autism MEAL Plan (behaviorally based parent-training curriculum)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Waitlist control (n = 9)
Number of subjects: 10
Study: 24294576

Group type: EXPERIMENTAL
Intervention: Glove finger packs (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Septal clips (Group B)
Number of subjects: 80
Study: 19940012

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily) with FOLFOX plus 5 mg/kg bevacizumab
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily) with FOLFOX plus 2 mg/kg bevacizumab
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily) with FOLFIRI
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily) with FOLFOX
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily)
Number of subjects: 30
Study: 18981327

Group type: EXPERIMENTAL
Intervention: Candesartan (16 to 32 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 to 50 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 12166578

Group type: EXPERIMENTAL
Intervention: Continuous oxygen therapy (COT) > or = 15 h daily
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Noncontinuous oxygen therapy (NCOT) <15 h daily
Number of subjects: 246
Study: 10622084

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin 50 IU
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin 100 IU
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 8075589

Group type: EXPERIMENTAL
Intervention: Purged Autologous Bone Marrow Transplantation (ABMT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 95
Study: 2587289

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (EX)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nonaerobic stretching and flexibility exercises (PL)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal activities (CO)
Number of subjects: 45
Study: 239907

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorazepate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31808947

Group type: COMPARATOR
Intervention: 0.5% NaOCl
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: 3% NaOCl
Number of subjects: 298
Study: 27620623

Group type: EXPERIMENTAL
Intervention: Family Checkup (FCU) intervention
Number of subjects: 731

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 731
Study: 25467591

Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg daily) and Elbasvir (50 mg daily) with ribavirin for 12 weeks
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg daily) and Elbasvir (50 mg daily) with ribavirin for 18 weeks
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg daily) and Elbasvir (50 mg daily) without ribavirin for 12 weeks
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 253
Study: 23242004

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg once daily for 5 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21103938

Group type: EXPERIMENTAL
Intervention: 250 mg/day terbinafine
Number of subjects: 304

Group type: COMPARATOR
Intervention: 100 mg/day itraconazole
Number of subjects: 304
Study: 19844077

Group type: EXPERIMENTAL
Intervention: Single, 2-hour educational programme conducted by a dermatologist or a dermatologist and a psychologist
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Single, 2-hour educational programme
Number of subjects: 123
Study: 17080254

Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine (LAC), n=13
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo, n=11
Number of subjects: 24
Study: 15271737

Group type: EXPERIMENTAL
Intervention: PCA with fentanyl 10 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PCA with fentanyl 20 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PCA with fentanyl 30 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PCA with fentanyl 40 microg
Number of subjects: 60
Study: 11711355

Group type: EXPERIMENTAL
Intervention: Abarelix 100 mg
Number of subjects: 269

Group type: COMPARATOR
Intervention: Leuprolide acetate 7.5 mg
Number of subjects: 269
Study: 9155219

Group type: EXPERIMENTAL
Intervention: Prepackaged diet plan
Number of subjects: 560

Group type: COMPARATOR
Intervention: Self-selected American Heart Association Step 1 and Step 2 diets
Number of subjects: 560
Study: 7957455

Group type: EXPERIMENTAL
Intervention: microencapsulated potassium chloride tablet (MET)
Number of subjects: 18

Group type: COMPARATOR
Intervention: potassium chloride solution (PS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: microencapsulated potassium chloride capsules (MEC)
Number of subjects: 18
Study: 3678046

Group type: EXPERIMENTAL
Intervention: Active marijuana (1.84% delta 9-THC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31563875

Group type: EXPERIMENTAL
Intervention: q‐FPs measured by dual‐photon microscopy
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Baseline q‐FPs
Number of subjects: 344

Group type: COMPARATOR
Intervention: q‐FPs and histological scoring
Number of subjects: 344
Study: 31170412

Group type: EXPERIMENTAL
Intervention: CDED plus 50% of calories from formula (Modulen, Nestlé) for 6 weeks followed by CDED with 25% PEN from weeks 7 to 12 (n = 40)
Number of subjects: 74

Group type: COMPARATOR
Intervention: EEN for 6 weeks followed by a free diet with 25% PEN from weeks 7 to 12 (n = 38)
Number of subjects: 74
Study: 27820922

Group type: EXPERIMENTAL
Intervention: Bortezomib plus Rituximab (B+R)
Number of subjects: 45
Study: 26521770

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Adaptive Pacing Therapy (APT)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Specialist Medical Care (SMC) alone
Number of subjects: 481
Study: 24179977

Group type: EXPERIMENTAL
Intervention: SurfLink-treated titanium dental implants
Number of subjects: 23

Group type: COMPARATOR
Intervention: Untreated control titanium dental implants
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups (SurfLink and control)
Number of subjects: 23
Study: 22008390

Group type: EXPERIMENTAL
Intervention: High-dose UFH (100 units kg(‐1) bolus, followed by 20 units kg h(‐1) continuous infusion)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Low-dose UFH (50 units kg(‐1) bolus)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: High-dose UFH
Number of subjects: 227

Group type: COMPARATOR
Intervention: Low-dose UFH
Number of subjects: 227
Study: 19428087

Group type: EXPERIMENTAL
Intervention: Pelvic plexus block with 2 mL of 2% lidocaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Periprostatic nerve block (PPNB) with 2 mL of 2% lidocaine
Number of subjects: 80
Study: 16716214

Group type: EXPERIMENTAL
Intervention: Low dose aspirin (100 mg daily for 5 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Medium dose aspirin (325 mg daily for 5 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Low dose aspirin vs Medium dose aspirin
Number of subjects: 72
Study: 14960530

Group type: EXPERIMENTAL
Intervention: TIPSS alone (group 1)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: TIPSS plus variceal band ligation (VBL) (group 2)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: TIPSS plus VBL (group 2)
Number of subjects: 79
Study: 11729022

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 60
Study: 9389342

Group type: EXPERIMENTAL
Intervention: ASTED system for sample preparation prior to HPLC
Number of subjects: 0
Study: 7906473

Group type: EXPERIMENTAL
Intervention: Topical betaxolol (0.5%) administered 5-6 hours before surgery
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Topical betaxolol (0.5%) administered 12 hours before surgery
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Topical betaxolol (0.5%) administered 24 hours before surgery
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Topical betaxolol (0.5%) administered 48 hours before surgery
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Topical betaxolol (0.5%) administered 4 hours before surgery into the contralateral eye
Number of subjects: 45
Study: 2886529

Group type: EXPERIMENTAL
Intervention: One dose of 500 mg metronidazole
Number of subjects: 440

Group type: COMPARATOR
Intervention: Zero, two, three, six, or twenty-one doses of metronidazole
Number of subjects: 440
Study: 29142012

Group type: EXPERIMENTAL
Intervention: Transcatheter interatrial shunt device (IASD)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 44
Study: 27203272

Group type: EXPERIMENTAL
Intervention: Shared decision support intervention using pamphlet and video decision aids for DT LVAD
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 168
Study: 25421542

Group type: EXPERIMENTAL
Intervention: Zoledronic acid administered once during preoperative hormonal therapy with letrozole for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study: 22401913

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine oestrogen (0.625 mg per day)
Number of subjects: 10739

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 10739
Study: 20885291

Group type: EXPERIMENTAL
Intervention: Scvo2-guided fluid therapy (crystalloid infusion 100 ml/h, bolus of 3 ml/kg hydroxyethyl starch if Scvo2 < 75%)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Traditional fluid regimen (crystalloid 800 ml/h, extra fluid for clinical signs of hypovolemia)
Number of subjects: 241
Study: 18523025

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 276

Group type: COMPARATOR
Intervention: White Light (WL)
Number of subjects: 276
Study: 17138193

Group type: EXPERIMENTAL
Intervention: Radial nerve injection (group RAD)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ulnar nerve injection (group ULN)
Number of subjects: 90
Study: 14732882

Group type: EXPERIMENTAL
Intervention: Biochemotherapy regimens combining IL‐2, IFN‐alpha and chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytokines alone (IL‐2 as a single agent or in combination with IFN‐alpha)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biotherapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy alone with additions (histamine or vaccines to IL‐2)
Number of subjects: 0
Study: 10761967

Group type: EXPERIMENTAL
Intervention: 3-g ginseng taken 40 minutes before glucose challenge
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 3-g ginseng taken together with glucose challenge
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 3-g ginseng taken before glucose challenge
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 19
Study: 8672407

Group type: EXPERIMENTAL
Intervention: Fat-replaced meal (3305 kJ, 54.6 g SPE, 24 g fat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control meal (5192 kJ, 73.2 g fat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat-replaced meal
Number of subjects: 0
Study: 1599343

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic intervention (weight reduction, sodium restriction, increased physical activity) consisting of eight weekly group sessions and two individual sessions followed by four monthly group sessions.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic intervention (weight reduction, sodium restriction, increased physical activity).
Number of subjects: 56
Study: 6532149

Group type: EXPERIMENTAL
Intervention: Response prevention treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Rapid smoking comparison treatment
Number of subjects: 39
Study: 30616899

Group type: EXPERIMENTAL
Intervention: Coaching care (CC) with weekly phone calls for 3 months
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard care (SC) with one day of therapeutic education and one phone call
Number of subjects: 8
Study: 30092590

Group type: EXPERIMENTAL
Intervention: IRE plus allogenic NK cells (IRE‐NK)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Simple IRE
Number of subjects: 40
Study: 27670796

Group type: EXPERIMENTAL
Intervention: Catheter closure of PDA using the standard technique (group 1)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Catheter closure of PDA using an exclusive venous approach (group 2)
Number of subjects: 112
Study: 24786935

Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Standard therapy (self-administered)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 244
Study: 22462640

Group type: EXPERIMENTAL
Intervention: Vitamin D status (25(OH)D levels) at 24-26 weeks of gestation
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (25(OH)D < 50 nmol/l) at 24-26 weeks of gestation
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Vitamin D status (25(OH)D levels) at 12-18 weeks of gestation
Number of subjects: 697